Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 clients • 6 examiners • 4 art units • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Double Helix Law has 5 pending office actions in Biotechnology & Pharmaceuticals. Its profile records 165 career applications, establishing a historical base for reviewing current prosecution activity.
The resolved allowance rate is 44.83%, and the average is 2.69 office actions per allowance. The allowance figure indicates that fewer than half of the recorded resolved applications reached allowance, while the office-action average shows that allowance generally followed more than one examination exchange. Practitioners should give particular attention to claim strategy, eligibility, and substantive examination issues in biotechnology and pharmaceutical matters.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
| CONIGLIO, AUDREA JUNE BUCKLEY | 1 | 53.1% | +20.6% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| TINSLEY, BRENDAN THOMAS | 1 | 60.4% | +74.3% |
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | KASAYAN, KATRIEL BARCELLANO | 54d |
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639281 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | TINSLEY, BRENDAN THOMAS | 134d overdue |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | BURKHART, MICHAEL D | 30d overdue |
| 18942965 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | PACKARD, BENJAMIN J | — |
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | — |
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | MATALKAH, FATIMAH KHALAF | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Lifeactive, Inc. | 2 |
| Cellphire | 2 |
| Exuma Biotech | 2 |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1634 | 2 |
| 1612 | 1 |
| 1617 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18942965 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | Lifeactive, Inc. | PACKARD, BENJAMIN J | 1612 | §103DP | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | Lifeactive, Inc. | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | Cellphire, Inc. | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | Cellphire, Inc. | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112Other | Non-Final OA | 54d | Pending | Jun 26, 2023 |
| 17639281 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | Exuma Biotech Corp. | TINSLEY, BRENDAN THOMAS | 1634 | §112 | Non-Final OA | 134d overdue | Pending | Feb 28, 2022 |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | Exuma Biotech Corp. | BURKHART, MICHAEL D | 1638 | §112 | Final Rejection | 30d overdue | Pending | Mar 01, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial44.8% of resolved applications prosecuted by Double Helix Law were allowed, across 165 applications in USPTO records.
2.69 office actions per allowed application on average.
6 pending office actions as of October 2026, for 3 clients, before 6 examiners in 4 art units.
